ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2; Q7Z5C3;
AC   Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   12-OCT-2022, entry version 264.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=Tropomyosin-related kinase A;
DE   AltName: Full=Tyrosine kinase receptor;
DE   AltName: Full=Tyrosine kinase receptor A;
DE            Short=Trk-A;
DE   AltName: Full=gp140trk {ECO:0000303|PubMed:2927393};
DE   AltName: Full=p140-TrkA;
DE   Flags: Precursor;
GN   Name=NTRK1;
GN   Synonyms=MTC, TRK {ECO:0000303|PubMed:2927393}, TRKA
GN   {ECO:0000303|PubMed:9290260};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I), CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Colon;
RX   PubMed=2927393; DOI=10.1128/mcb.9.1.24-33.1989;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9290260; DOI=10.1007/bf02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high affinity
RT   receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 1-175 (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates TrkA
RT   gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION WITH
RP   TPM3.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and protein
RT   tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   PubMed=2966065; DOI=10.1002/j.1460-2075.1988.tb02794.x;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION WITH
RP   TFG.
RX   PubMed=7565764; DOI=10.1128/mcb.15.11.6118;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a novel
RT   gene on chromosome 3 whose product has a potential coiled-coil domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT WITH
RP   TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in
RT   human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION AS RECEPTOR FOR NGF.
RX   PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-oncogene
RT   and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION IN NGF SIGNALING, AND IDENTIFICATION AS THE HIGH AFFINITY NGF
RP   RECEPTOR.
RX   PubMed=1849459; DOI=10.1016/0092-8674(91)90419-y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   FUNCTION, SUBUNIT, CATALYTIC ACTIVITY, PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-544.
RX   PubMed=1281417; DOI=10.1016/0896-6273(92)90066-m;
RA   Jing S., Tapley P., Barbacid M.;
RT   "Nerve growth factor mediates signal transduction through trk homodimer
RT   receptors.";
RL   Neuron 9:1067-1079(1992).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II), FUNCTION IN CELL
RP   SURVIVAL, NGF-BINDING, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8325889; DOI=10.1016/s0021-9258(18)82449-8;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the trkA
RT   receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [16]
RP   PHOSPHORYLATION AT TYR-791, INTERACTION WITH PLCG1, AND MUTAGENESIS OF
RP   TYR-791.
RX   PubMed=7510697; DOI=10.1016/s0021-9258(17)37053-9;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin
RT   induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [17]
RP   FUNCTION IN NEURONAL DIFFERENTIATION, FUNCTION IN PHOSPHORYLATION OF SHC1
RP   AND PLCG1, INTERACTION WITH SHC1, MUTAGENESIS OF TYR-496; LYS-544 AND
RP   TYR-791, AND PHOSPHORYLATION AT TYR-496; TYR-676; TYR-680; TYR-681 AND
RP   TYR-791.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving SHC and
RT   PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [18]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.c000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T., Barker P.A.,
RA   Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold for
RT   NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [19]
RP   FUNCTION IN NEURONAL CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION IN
RP   SIGNALING CASCADE ACTIVATION, NGF-BINDING, SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING (ISOFORM TRKA-III), CHARACTERIZATION OF ISOFORM
RP   TRKA-III, PHOSPHORYLATION AT TYR-496; TYR-680; TYR-681 AND TYR-791,
RP   INTERACTION WITH FRS2; GRB2; PIK3R1; PLCG1; SHC1, GLYCOSYLATION, TISSUE
RP   SPECIFICITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in human
RT   neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [20]
RP   INTERACTION WITH SORT1, AND ACTIVITY REGULATION.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S., Kjolby M.,
RA   Richner M., Erdmann B., Nyengaard J.R., Tessarollo L., Lewin G.R.,
RA   Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde transport
RT   and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH NGF.
RX   PubMed=22649032; DOI=10.1096/fj.12-207316;
RA   Tong Q., Wang F., Zhou H.Z., Sun H.L., Song H., Shu Y.Y., Gong Y.,
RA   Zhang W.T., Cai T.X., Yang F.Q., Tang J., Jiang T.;
RT   "Structural and functional insights into lipid-bound nerve growth
RT   factors.";
RL   FASEB J. 26:3811-3821(2012).
RN   [22]
RP   INTERACTION WITH GGA3, AND MUTAGENESIS OF 540-LEU-VAL-541; LYS-544 AND
RP   610-LEU-LEU-611.
RX   PubMed=26446845; DOI=10.1091/mbc.e15-02-0087;
RA   Li X., Lavigne P., Lavoie C.;
RT   "GGA3 mediates TrkA endocytic recycling to promote sustained Akt
RT   phosphorylation and cell survival.";
RL   Mol. Biol. Cell 26:4412-4426(2015).
RN   [23]
RP   FUNCTION, UBIQUITINATION BY NEDD4L, AND INTERACTION WITH USP36.
RX   PubMed=27445338; DOI=10.1074/jbc.m116.722637;
RA   Anta B., Martin-Rodriguez C., Gomis-Perez C., Calvo L., Lopez-Benito S.,
RA   Calderon-Garcia A.A., Vicente-Garcia C., Villarroel A., Arevalo J.C.;
RT   "Ubiquitin-specific Protease 36 (USP36) Controls Neuronal Precursor Cell-
RT   expressed Developmentally Down-regulated 4-2 (Nedd4-2) Actions over the
RT   Neurotrophin Receptor TrkA and Potassium Voltage-gated Channels 7.2/3
RT   (Kv7.2/3).";
RL   J. Biol. Chem. 291:19132-19145(2016).
RN   [24]
RP   PHOSPHORYLATION, VARIANTS CIPA 235-SER--GLY-796 DEL; ASN-596 AND TYR-674,
RP   AND CHARACTERIZATION OF VARIANTS CIPA 235-SER--GLY-796 DEL AND ASN-596.
RX   PubMed=28177573; DOI=10.1111/jns.12205;
RA   Nam T.S., Li W., Yoon S., Eom G.H., Kim M.K., Jung S.T., Choi S.Y.;
RT   "Novel NTRK1 mutations associated with congenital insensitivity to pain
RT   with anhidrosis verified by functional studies.";
RL   J. Peripher. Nerv. Syst. 22:92-99(2017).
RN   [25]
RP   STRUCTURE BY NMR OF 489-500.
RX   PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M., Meadows R.P.,
RA   Sattler M., Harlan J.E., Wade W.S., Burakoff S.J., Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding domain of
RT   Shc.";
RL   Nature 378:584-592(1995).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 278-386, AND DISULFIDE BONDS.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D.,
RA   Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and
RT   TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 282-382 IN COMPLEX WITH NGF,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   HOMODIMERIZATION, SUBUNIT, SUBCELLULAR LOCATION, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-95; ASN-121; ASN-188; ASN-262; ASN-281 AND ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor interactions
RT   with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [29]
RP   VARIANT CIPA ARG-577.
RX   PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [30]
RP   VARIANT CIPA PRO-780.
RX   PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to pain
RT   with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [31]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85; TYR-604
RP   AND VAL-613.
RX   PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P., Moosa A.,
RA   Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W., Graham G.E.,
RA   Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in the
RT   TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth
RT   factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [32]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   PubMed=10443680; DOI=10.1210/jcem.84.8.5901;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in sporadic
RT   human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [33]
RP   VARIANT CIPA VAL-587.
RX   PubMed=10233776; DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the TRKA
RT   gene in a family with congenital insensitivity to pain with anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [34]
RP   VARIANTS TYR-604 AND VAL-613.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [35]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [36]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::aid-ajmg12>3.0.co;2-c;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF receptor
RT   gene, clinical findings, and results of nerve conduction studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [37]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding a
RT   high-affinity receptor for nerve growth factor in congenital insensitivity
RT   to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [38]
RP   VARIANT CIPA ARG-577.
RX   PubMed=10567924;
RX   DOI=10.1002/(sici)1097-4652(200001)182:1<127::aid-jcp14>3.0.co;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory disorder
RT   congenital insensitivity to pain with anhidrosis, causes the inactivation
RT   of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [39]
RP   VARIANT CIPA CYS-359, AND VARIANTS TYR-604 AND VAL-613.
RX   PubMed=11310631; DOI=10.1002/ana.103;
RA   Houlden H., King R.H., Hashemi-Nejad A., Wood N.W., Mathias C.J.,
RA   Reilly M., Thomas P.K.;
RT   "A novel TRK A (NTRK1) mutation associated with hereditary sensory and
RT   autonomic neuropathy type V.";
RL   Ann. Neurol. 49:521-525(2001).
RN   [40]
RP   CHARACTERIZATION OF VARIANTS CIPA PRO-93; PRO-213; ARG-522; ARG-577;
RP   TRP-649; CYS-654 AND SER-714, AND CHARACTERIZATION OF VARIANTS SER-85;
RP   TYR-604; VAL-613 AND TYR-674.
RX   PubMed=11159935; DOI=10.1093/hmg/10.3.179;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA): effect of TRKA
RT   (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine
RT   kinase for nerve growth factor.";
RL   Hum. Mol. Genet. 10:179-188(2001).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238; GLY-260;
RP   GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [42]
RP   VARIANTS CIPA SER-572 AND ARG-717.
RX   PubMed=18077166; DOI=10.1016/j.nmd.2007.10.005;
RA   Huehne K., Zweier C., Raab K., Odent S., Bonnaure-Mallet M., Sixou J.L.,
RA   Landrieu P., Goizet C., Sarlangue J., Baumann M., Eggermann T., Rauch A.,
RA   Ruppert S., Stettner G.M., Rautenstrauss B.;
RT   "Novel missense, insertion and deletion mutations in the neurotrophic
RT   tyrosine kinase receptor type 1 gene (NTRK1) associated with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Neuromuscul. Disord. 18:159-166(2008).
RN   [43]
RP   VARIANTS CIPA LYS-492 AND CYS-654, AND VARIANT TRP-6.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A., Muntoni F.,
RA   Blake J., Brandner S., Davies N., Horvath R., Price S., Donaghy M.,
RA   Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P., Manji H.,
RA   Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary sensory and
RT   autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [44]
RP   VARIANTS CIPA ASP-110; 146-SER--GLY-796 DEL; 176-GLN--GLY-796 DEL;
RP   476-LEU--GLY-796 DEL; GLN-649 AND PRO-700.
RX   PubMed=28328124; DOI=10.1002/ajmg.a.38120;
RA   Altassan R., Saud H.A., Masoodi T.A., Dosssari H.A., Khalifa O.,
RA   Al-Zaidan H., Sakati N., Rhabeeni Z., Al-Hassnan Z., Binamer Y.,
RA   Alhashemi N., Wade W., Al-Zayed Z., Al-Sayed M., Al-Muhaizea M.A.,
RA   Meyer B., Al-Owain M., Wakil S.M.;
RT   "Exome sequencing identifies novel NTRK1 mutations in patients with HSAN-IV
RT   phenotype.";
RL   Am. J. Med. Genet. A 173:1009-1016(2017).
RN   [45]
RP   VARIANTS CIPA GLU-517; GLU-522; PRO-657; THR-699; SER-752; SER-763 AND
RP   CYS-771, CHARACTERIZATION OF VARIANTS CIPA GLU-517; GLU-522; PRO-657;
RP   THR-699; SER-752; SER-763 AND CYS-771, GLYCOSYLATION, SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION AFTER NGF STIMULATION, AND FUNCTION.
RX   PubMed=27676246; DOI=10.1002/humu.23123;
RA   Shaikh S.S., Chen Y.C., Halsall S.A., Nahorski M.S., Omoto K., Young G.T.,
RA   Phelan A., Woods C.G.;
RT   "A comprehensive functional analysis of NTRK1 missense mutations causing
RT   hereditary sensory and autonomic neuropathy type IV (HSAN IV).";
RL   Hum. Mutat. 38:55-63(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and the
CC       maturation of the central and peripheral nervous systems through
CC       regulation of proliferation, differentiation and survival of
CC       sympathetic and nervous neurons. High affinity receptor for NGF which
CC       is its primary ligand (PubMed:1850821, PubMed:1849459, PubMed:1281417,
CC       PubMed:8325889, PubMed:15488758, PubMed:22649032, PubMed:17196528,
CC       PubMed:27445338). Can also bind and be activated by NTF3/neurotrophin-
CC       3. However, NTF3 only supports axonal extension through NTRK1 but has
CC       no effect on neuron survival (By similarity). Upon dimeric NGF ligand-
CC       binding, undergoes homodimerization, autophosphorylation and activation
CC       (PubMed:1281417). Recruits, phosphorylates and/or activates several
CC       downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that
CC       regulate distinct overlapping signaling cascades driving cell survival
CC       and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK
CC       cascade that regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes involved
CC       in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1
CC       signaling cascade that is also regulating survival. In absence of
CC       ligand and activation, may promote cell death, making the survival of
CC       neurons dependent on trophic factors. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459,
CC       ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:22649032,
CC       ECO:0000269|PubMed:27445338, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- FUNCTION: [Isoform TrkA-III]: Resistant to NGF, it constitutively
CC       activates AKT1 and NF-kappa-B and is unable to activate the Ras-MAPK
CC       signaling cascade. Antagonizes the anti-proliferative NGF-NTRK1
CC       signaling that promotes neuronal precursors differentiation. Isoform
CC       TrkA-III promotes angiogenesis and has oncogenic activity when
CC       overexpressed. {ECO:0000269|PubMed:15488758}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
CC   -!- ACTIVITY REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes and its
CC       retrograde axonal transport. This is regulated by different proteins
CC       including CFL1, RAC1 and SORT1. NTF3 is unable to induce this signaling
CC       probably due to the lability of the NTF3-NTRK1 complex in endosomes.
CC       SH2D1A inhibits the autophosphorylation of the receptor, and alters the
CC       recruitment and activation of downstream effectors and signaling
CC       cascades (By similarity). Regulated by NGFR (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization is
CC       induced by binding of a NGF dimer (PubMed:1281417, PubMed:10490030,
CC       PubMed:17196528). Interacts with SQSTM1; bridges NTRK1 to NGFR
CC       (PubMed:11244088). Forms a ternary complex with NGFR and KIDINS220;
CC       this complex is affected by the expression levels of KIDINS220 and an
CC       increase in KIDINS220 expression leads to a decreased association of
CC       NGFR and NTRK1 (By similarity). Interacts with SH2D1A; regulates NTRK1
CC       (By similarity). Interacts (phosphorylated upon activation by NGF) with
CC       SHC1; mediates SHC1 phosphorylation and activation (PubMed:8155326,
CC       PubMed:15488758). Interacts (phosphorylated upon activation by NGF)
CC       with PLCG1; mediates PLCG1 phosphorylation and activation
CC       (PubMed:7510697, PubMed:15488758). Interacts (phosphorylated) with
CC       SH2B1 and SH2B2 (By similarity). Interacts with GRB2 (PubMed:15488758).
CC       Interacts with PIK3R1 (PubMed:15488758). Interacts with FRS2
CC       (PubMed:15488758). Interacts with SORT1; may regulate NTRK1 anterograde
CC       axonal transport (PubMed:21102451). Interacts with RAB7A (By
CC       similarity). Found in a complex, at least composed of KIDINS220, MAGI2,
CC       NTRK1 and RAPGEF2; the complex is mainly formed at late endosomes in a
CC       nerve growth factor (NGF)-dependent manner (By similarity). Interacts
CC       with RAPGEF2; the interaction is strengthened after NGF stimulation (By
CC       similarity). Interacts with PTPRS (By similarity). Interacts with
CC       USP36; USP36 does not deubiquitinate NTRK1 (PubMed:27445338). Interacts
CC       with GGA3 (PubMed:26446845). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P35739, ECO:0000269|PubMed:10490030,
CC       ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:21102451, ECO:0000269|PubMed:22649032,
CC       ECO:0000269|PubMed:26446845, ECO:0000269|PubMed:27445338,
CC       ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INTERACTION:
CC       P04629; P05067-4: APP; NbExp=7; IntAct=EBI-1028226, EBI-302641;
CC       P04629; P22681: CBL; NbExp=2; IntAct=EBI-1028226, EBI-518228;
CC       P04629; P08238: HSP90AB1; NbExp=3; IntAct=EBI-1028226, EBI-352572;
CC       P04629; P01138: NGF; NbExp=3; IntAct=EBI-1028226, EBI-1028250;
CC       P04629; PRO_0000019600 [P01138]: NGF; NbExp=2; IntAct=EBI-1028226, EBI-9249861;
CC       P04629; P04629: NTRK1; NbExp=3; IntAct=EBI-1028226, EBI-1028226;
CC       P04629; Q16288: NTRK3; NbExp=2; IntAct=EBI-1028226, EBI-3936704;
CC       P04629; P27986: PIK3R1; NbExp=4; IntAct=EBI-1028226, EBI-79464;
CC       P04629; P19174: PLCG1; NbExp=4; IntAct=EBI-1028226, EBI-79387;
CC       P04629; P18031: PTPN1; NbExp=2; IntAct=EBI-1028226, EBI-968788;
CC       P04629; Q99523: SORT1; NbExp=3; IntAct=EBI-1028226, EBI-1057058;
CC       P04629; Q13501: SQSTM1; NbExp=2; IntAct=EBI-1028226, EBI-307104;
CC       P04629; O75385: ULK1; NbExp=2; IntAct=EBI-1028226, EBI-908831;
CC       P04629; Q8K4V6: Pirb; Xeno; NbExp=2; IntAct=EBI-1028226, EBI-8602514;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:2927393}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Late endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Recycling endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane protein
CC       {ECO:0000250|UniProtKB:P35739}. Note=Rapidly internalized after NGF
CC       binding (PubMed:1281417). Internalized to endosomes upon binding of NGF
CC       or NTF3 and further transported to the cell body via a retrograde
CC       axonal transport. Localized at cell membrane and early endosomes before
CC       nerve growth factor (NGF) stimulation. Recruited to late endosomes
CC       after NGF stimulation. Colocalized with RAPGEF2 at late endosomes.
CC       {ECO:0000250|UniProtKB:P35739, ECO:0000269|PubMed:1281417}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=TrkA-I and TrkA-II isoforms have similar biological
CC         properties but are differentially expressed.;
CC       Name=TrkA-II; Synonyms=TrkAII;
CC         IsoId=P04629-1; Sequence=Displayed;
CC       Name=TrkA-I; Synonyms=TrkAI;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC       Name=3;
CC         IsoId=P04629-3; Sequence=VSP_041905, VSP_002899;
CC       Name=TrkA-III; Synonyms=TrkAIII;
CC         IsoId=P04629-4; Sequence=VSP_042152, VSP_002899;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-I is found in most non-neuronal
CC       tissues. Isoform TrkA-II is primarily expressed in neuronal cells.
CC       TrkA-III is specifically expressed by pluripotent neural stem and
CC       neural crest progenitors. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INDUCTION: Isoform TrkA-III is up-regulated upon hypoxia in cells
CC       normally expressing it. {ECO:0000269|PubMed:15488758}.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with KIDINS220.
CC       {ECO:0000250|UniProtKB:P35739}.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC       {ECO:0000250|UniProtKB:P35739}.
CC   -!- PTM: Ligand-mediated autophosphorylation (PubMed:2927393,
CC       PubMed:1281417, PubMed:15488758, PubMed:7510697, PubMed:8155326,
CC       PubMed:8325889, PubMed:27676246, PubMed:28177573). Interaction with
CC       SQSTM1 is phosphotyrosine-dependent. Autophosphorylation at Tyr-496
CC       mediates interaction and phosphorylation of SHC1 (PubMed:15488758,
CC       PubMed:7510697, PubMed:8155326, PubMed:8325889).
CC       {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:2927393, ECO:0000269|PubMed:7510697,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- PTM: N-glycosylated (PubMed:2927393). Isoform TrkA-I and isoform TrkA-
CC       II are N-glycosylated. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- PTM: Ubiquitinated (PubMed:27445338). Undergoes polyubiquitination upon
CC       activation; regulated by NGFR (PubMed:27445338). Ubiquitination by
CC       NEDD4L leads to degradation (PubMed:27445338). Ubiquitination regulates
CC       the internalization of the receptor (By similarity).
CC       {ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:27445338}.
CC   -!- DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA)
CC       [MIM:256800]: Characterized by a congenital insensitivity to pain,
CC       anhidrosis (absence of sweating), absence of reaction to noxious
CC       stimuli, self-mutilating behavior, and intellectual disability. This
CC       rare autosomal recessive disorder is also known as congenital sensory
CC       neuropathy with anhidrosis or hereditary sensory and autonomic
CC       neuropathy type IV or familial dysautonomia type II.
CC       {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776,
CC       ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924,
CC       ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191,
CC       ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
CC       ECO:0000269|PubMed:18077166, ECO:0000269|PubMed:22302274,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:28328124, ECO:0000269|PubMed:8696348}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in
CC       papillary thyroid carcinomas (PTCs) (PubMed:2869410, PubMed:7565764,
CC       PubMed:1532241). Translocation t(1;3)(q21;q11) with TFG generates the
CC       TRKT3 (TRK-T3) transcript by fusing TFG to the 3'-end of NTRK1
CC       (PubMed:7565764). A rearrangement with TPM3 generates the TRK
CC       transcript by fusing TPM3 to the 3'-end of NTRK1 (PubMed:2869410). An
CC       intrachromosomal rearrangement that links the protein kinase domain of
CC       NTRK1 to the 5'-end of the TPR gene forms the fusion protein TRK-T1.
CC       TRK-T1 is a 55 kDa protein reacting with antibodies against the C-
CC       terminus of the NTRK1 protein (PubMed:1532241).
CC       {ECO:0000269|PubMed:1532241, ECO:0000269|PubMed:2869410,
CC       ECO:0000269|PubMed:7565764}.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since it
CC       was first isolated as an oncogenic protein which was the result of a
CC       fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- MISCELLANEOUS: [Isoform TrkA-II]: Major isoform.
CC   -!- MISCELLANEOUS: [Isoform TrkA-I]: Has enhanced responsiveness to NTF3
CC       neurotrophin. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform TrkA-III]: Constitutively active. Does not bind
CC       NGF and does not interact with GRB2 and FRS2. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27243.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA29888.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA44719.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA59936.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; DB265639; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL158169; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062580; AAH62580.1; -; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_SEQ; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_SEQ; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_SEQ; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1161.1; -. [P04629-1]
DR   CCDS; CCDS30890.1; -. [P04629-3]
DR   CCDS; CCDS30891.1; -. [P04629-2]
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; NM_001007792.1. [P04629-3]
DR   RefSeq; NP_001012331.1; NM_001012331.1. [P04629-2]
DR   RefSeq; NP_002520.2; NM_002529.3. [P04629-1]
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDB; 2N90; NMR; -; A/B=410-447.
DR   PDB; 4AOJ; X-ray; 2.75 A; A/B/C=473-796.
DR   PDB; 4CRP; NMR; -; A=282-383.
DR   PDB; 4F0I; X-ray; 2.30 A; A/B=498-796.
DR   PDB; 4GT5; X-ray; 2.40 A; A=498-796.
DR   PDB; 4PMM; X-ray; 2.00 A; A=501-787.
DR   PDB; 4PMP; X-ray; 1.80 A; A=501-787.
DR   PDB; 4PMS; X-ray; 2.80 A; A=501-787.
DR   PDB; 4PMT; X-ray; 2.10 A; A=501-787.
DR   PDB; 4YNE; X-ray; 2.02 A; A=502-796.
DR   PDB; 4YPS; X-ray; 2.10 A; A=502-796.
DR   PDB; 5H3Q; X-ray; 2.10 A; A=473-796.
DR   PDB; 5I8A; X-ray; 2.33 A; A=498-787.
DR   PDB; 5JFS; X-ray; 2.07 A; A=502-796.
DR   PDB; 5JFV; X-ray; 1.59 A; A=502-796.
DR   PDB; 5JFW; X-ray; 1.52 A; A=502-796.
DR   PDB; 5JFX; X-ray; 1.63 A; A=502-796.
DR   PDB; 5KMI; X-ray; 1.87 A; A=474-796.
DR   PDB; 5KMJ; X-ray; 2.04 A; A=474-796.
DR   PDB; 5KMK; X-ray; 2.24 A; A=474-796.
DR   PDB; 5KML; X-ray; 2.01 A; A=474-796.
DR   PDB; 5KMM; X-ray; 2.12 A; A=474-796.
DR   PDB; 5KMN; X-ray; 2.14 A; A=474-796.
DR   PDB; 5KMO; X-ray; 2.67 A; A=474-796.
DR   PDB; 5KVT; X-ray; 2.45 A; A=501-787.
DR   PDB; 5WR7; X-ray; 2.76 A; A=489-792.
DR   PDB; 6D1Y; X-ray; 1.93 A; A=479-796.
DR   PDB; 6D1Z; X-ray; 1.87 A; A=479-796.
DR   PDB; 6D20; X-ray; 1.94 A; A=479-796.
DR   PDB; 6D22; X-ray; 2.46 A; A=502-796.
DR   PDB; 6DKB; X-ray; 2.68 A; A=479-796.
DR   PDB; 6DKG; X-ray; 2.53 A; A=479-796.
DR   PDB; 6DKI; X-ray; 2.11 A; A=479-796.
DR   PDB; 6DKW; X-ray; 2.91 A; A/B=502-796.
DR   PDB; 6IQN; X-ray; 2.54 A; A/B=502-796.
DR   PDB; 6J5L; X-ray; 2.30 A; A=502-796.
DR   PDB; 6NPT; X-ray; 2.19 A; A=491-795.
DR   PDB; 6NSP; X-ray; 2.31 A; A=500-796.
DR   PDB; 6NSS; X-ray; 1.97 A; A=485-795.
DR   PDB; 6PL1; X-ray; 2.03 A; A=485-795.
DR   PDB; 6PL2; X-ray; 2.59 A; A=485-795.
DR   PDB; 6PL3; X-ray; 3.00 A; A=485-795.
DR   PDB; 6PL4; X-ray; 2.06 A; A=485-795.
DR   PDB; 6PMA; X-ray; 2.53 A; A=485-795.
DR   PDB; 6PMB; X-ray; 2.81 A; A=485-795.
DR   PDB; 6PMC; X-ray; 2.19 A; A=485-795.
DR   PDB; 6PME; X-ray; 3.00 A; A/B/C=485-795.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   PDBsum; 2N90; -.
DR   PDBsum; 4AOJ; -.
DR   PDBsum; 4CRP; -.
DR   PDBsum; 4F0I; -.
DR   PDBsum; 4GT5; -.
DR   PDBsum; 4PMM; -.
DR   PDBsum; 4PMP; -.
DR   PDBsum; 4PMS; -.
DR   PDBsum; 4PMT; -.
DR   PDBsum; 4YNE; -.
DR   PDBsum; 4YPS; -.
DR   PDBsum; 5H3Q; -.
DR   PDBsum; 5I8A; -.
DR   PDBsum; 5JFS; -.
DR   PDBsum; 5JFV; -.
DR   PDBsum; 5JFW; -.
DR   PDBsum; 5JFX; -.
DR   PDBsum; 5KMI; -.
DR   PDBsum; 5KMJ; -.
DR   PDBsum; 5KMK; -.
DR   PDBsum; 5KML; -.
DR   PDBsum; 5KMM; -.
DR   PDBsum; 5KMN; -.
DR   PDBsum; 5KMO; -.
DR   PDBsum; 5KVT; -.
DR   PDBsum; 5WR7; -.
DR   PDBsum; 6D1Y; -.
DR   PDBsum; 6D1Z; -.
DR   PDBsum; 6D20; -.
DR   PDBsum; 6D22; -.
DR   PDBsum; 6DKB; -.
DR   PDBsum; 6DKG; -.
DR   PDBsum; 6DKI; -.
DR   PDBsum; 6DKW; -.
DR   PDBsum; 6IQN; -.
DR   PDBsum; 6J5L; -.
DR   PDBsum; 6NPT; -.
DR   PDBsum; 6NSP; -.
DR   PDBsum; 6NSS; -.
DR   PDBsum; 6PL1; -.
DR   PDBsum; 6PL2; -.
DR   PDBsum; 6PL3; -.
DR   PDBsum; 6PL4; -.
DR   PDBsum; 6PMA; -.
DR   PDBsum; 6PMB; -.
DR   PDBsum; 6PMC; -.
DR   PDBsum; 6PME; -.
DR   AlphaFoldDB; P04629; -.
DR   BMRB; P04629; -.
DR   SMR; P04629; -.
DR   BioGRID; 110969; 1963.
DR   CORUM; P04629; -.
DR   DIP; DIP-5714N; -.
DR   ELM; P04629; -.
DR   IntAct; P04629; 213.
DR   MINT; P04629; -.
DR   STRING; 9606.ENSP00000431418; -.
DR   BindingDB; P04629; -.
DR   ChEMBL; CHEMBL2815; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB13926; Cenegermin.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB14723; Larotrectinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugCentral; P04629; -.
DR   GuidetoPHARMACOLOGY; 1817; -.
DR   GlyGen; P04629; 13 sites.
DR   iPTMnet; P04629; -.
DR   PhosphoSitePlus; P04629; -.
DR   BioMuta; NTRK1; -.
DR   DMDM; 94730402; -.
DR   MassIVE; P04629; -.
DR   PaxDb; P04629; -.
DR   PeptideAtlas; P04629; -.
DR   PRIDE; P04629; -.
DR   ProteomicsDB; 51723; -. [P04629-1]
DR   ProteomicsDB; 51724; -. [P04629-2]
DR   ProteomicsDB; 51725; -. [P04629-3]
DR   ProteomicsDB; 51726; -. [P04629-4]
DR   ABCD; P04629; 33 sequenced antibodies.
DR   Antibodypedia; 3896; 1649 antibodies from 44 providers.
DR   DNASU; 4914; -.
DR   Ensembl; ENST00000368196.7; ENSP00000357179.3; ENSG00000198400.13. [P04629-2]
DR   Ensembl; ENST00000524377.7; ENSP00000431418.1; ENSG00000198400.13. [P04629-1]
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   MANE-Select; ENST00000524377.7; ENSP00000431418.1; NM_002529.4; NP_002520.2.
DR   UCSC; uc001fqf.2; human. [P04629-1]
DR   CTD; 4914; -.
DR   DisGeNET; 4914; -.
DR   GeneCards; NTRK1; -.
DR   GeneReviews; NTRK1; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; ENSG00000198400; Group enriched (adrenal gland, brain).
DR   MalaCards; NTRK1; -.
DR   MIM; 164970; gene.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   neXtProt; NX_P04629; -.
DR   OpenTargets; ENSG00000198400; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   PharmGKB; PA31817; -.
DR   VEuPathDB; HostDB:ENSG00000198400; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   GeneTree; ENSGT00940000159412; -.
DR   HOGENOM; CLU_000288_74_1_1; -.
DR   InParanoid; P04629; -.
DR   OMA; IMLKWEL; -.
DR   OrthoDB; 295510at2759; -.
DR   PhylomeDB; P04629; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P04629; -.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-170968; Frs2-mediated activation. [P04629-1]
DR   Reactome; R-HSA-170984; ARMS-mediated activation.
DR   Reactome; R-HSA-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-187042; TRKA activation by NGF.
DR   Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   SignaLink; P04629; -.
DR   SIGNOR; P04629; -.
DR   BioGRID-ORCS; 4914; 14 hits in 1111 CRISPR screens.
DR   ChiTaRS; NTRK1; human.
DR   EvolutionaryTrace; P04629; -.
DR   GenomeRNAi; 4914; -.
DR   Pharos; P04629; Tclin.
DR   PRO; PR:P04629; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P04629; protein.
DR   Bgee; ENSG00000198400; Expressed in dorsal root ganglion and 94 other tissues.
DR   ExpressionAtlas; P04629; baseline and differential.
DR   Genevisible; P04629; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0032991; C:protein-containing complex; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0055038; C:recycling endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central.
DR   GO; GO:0005166; F:neurotrophin p75 receptor binding; IEA:Ensembl.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ARUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0048666; P:neuron development; IDA:MGI.
DR   GO; GO:0031175; P:neuron projection development; IDA:MGI.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:MGI.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0010623; P:programmed cell death involved in cell development; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0060009; P:Sertoli cell development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   IDEAL; IID00535; -.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR020777; NTRK.
DR   InterPro; IPR020461; NTRK1.
DR   InterPro; IPR031635; NTRK_LRRCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR040665; TrkA_TMD.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF16920; LRRCT_2; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF18613; TrkA_TMD; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Developmental protein; Differentiation;
KW   Disease variant; Disulfide bond; Endosome; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000255"
FT   CHAIN           33..796
FT                   /note="High affinity nerve growth factor receptor"
FT                   /id="PRO_0000016724"
FT   TOPO_DOM        33..423
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        424..439
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        440..796
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          90..113
FT                   /note="LRR 1"
FT   REPEAT          116..137
FT                   /note="LRR 2"
FT   DOMAIN          148..193
FT                   /note="LRRCT"
FT   DOMAIN          194..283
FT                   /note="Ig-like C2-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          299..365
FT                   /note="Ig-like C2-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DOMAIN          510..781
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          469..490
FT                   /note="Interaction with SQSTM1"
FT                   /evidence="ECO:0000250"
FT   MOTIF           537..541
FT                   /note="DXXLL"
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MOTIF           607..611
FT                   /note="DXXLL"
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   ACT_SITE        650
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         516..524
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         544
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            398..399
FT                   /note="Breakpoint for translocation to form TRK and TRK-T3"
FT   SITE            486
FT                   /note="Breakpoint for translocation to form TRK-T1"
FT   SITE            496
FT                   /note="Interaction with SHC1"
FT   SITE            791
FT                   /note="Interaction with PLCG1"
FT   MOD_RES         496
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:8155326"
FT   MOD_RES         676
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8155326"
FT   MOD_RES         680
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:8155326"
FT   MOD_RES         681
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:8155326"
FT   MOD_RES         791
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15488758,
FT                   ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326"
FT   CARBOHYD        67
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        95
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528,
FT                   ECO:0007744|PDB:2IFG"
FT   CARBOHYD        202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        253
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528,
FT                   ECO:0007744|PDB:2IFG"
FT   CARBOHYD        281
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528,
FT                   ECO:0007744|PDB:2IFG"
FT   CARBOHYD        318
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        323
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        358
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17196528,
FT                   ECO:0007744|PDB:2IFG"
FT   CARBOHYD        401
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..41
FT                   /evidence="ECO:0007744|PDB:2IFG"
FT   DISULFID        40..50
FT                   /evidence="ECO:0007744|PDB:2IFG"
FT   DISULFID        154..191
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17196528, ECO:0007744|PDB:2IFG"
FT   DISULFID        215..265
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:17196528, ECO:0007744|PDB:2IFG"
FT   DISULFID        300..345
FT                   /evidence="ECO:0007744|PDB:1HE7, ECO:0007744|PDB:1WWA,
FT                   ECO:0007744|PDB:1WWW, ECO:0007744|PDB:2IFG,
FT                   ECO:0007744|PDB:4CRP"
FT   VAR_SEQ         1..71
FT                   /note="MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTR
FT                   DGALDSLHHLPGAENLTEL -> MKEAALICLAPSVPPILTVKSWDTMQLRAARSRCTN
FT                   LLAAS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041905"
FT   VAR_SEQ         192..284
FT                   /note="GVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMKSGG
FT                   LPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSF -> V (in isoform
FT                   TrkA-III)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042152"
FT   VAR_SEQ         393..398
FT                   /note="Missing (in isoform TrkA-I, isoform 3 and isoform
FT                   TrkA-III)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:2927393"
FT                   /id="VSP_002899"
FT   VARIANT         6
FT                   /note="R -> W (in dbSNP:rs201472270)"
FT                   /evidence="ECO:0000269|PubMed:22302274"
FT                   /id="VAR_068480"
FT   VARIANT         18
FT                   /note="G -> E (in dbSNP:rs1007211)"
FT                   /id="VAR_049714"
FT   VARIANT         80
FT                   /note="Q -> R (in dbSNP:rs55891455)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041461"
FT   VARIANT         85
FT                   /note="R -> S (in dbSNP:rs543320028)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009623"
FT   VARIANT         93
FT                   /note="L -> P (in CIPA; aberrantly processed; shows
FT                   diminished autophosphorylation in neuronal cells)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009624"
FT   VARIANT         107
FT                   /note="A -> V (in an ovarian serous carcinoma sample;
FT                   somatic mutation; dbSNP:rs540521894)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041462"
FT   VARIANT         110
FT                   /note="A -> D (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079399"
FT   VARIANT         146..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079400"
FT   VARIANT         176..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079401"
FT   VARIANT         213
FT                   /note="L -> P (in CIPA; aberrantly processed; shows
FT                   diminished autophosphorylation in neuronal cells;
FT                   dbSNP:rs747711259)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009625"
FT   VARIANT         235..796
FT                   /note="Missing (in CIPA; loss of protein)"
FT                   /evidence="ECO:0000269|PubMed:28177573"
FT                   /id="VAR_079402"
FT   VARIANT         237
FT                   /note="T -> M (in dbSNP:rs55909005)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041463"
FT   VARIANT         238
FT                   /note="V -> G (in dbSNP:rs56000394)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041464"
FT   VARIANT         260
FT                   /note="R -> G (in dbSNP:rs35116695)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041465"
FT   VARIANT         359
FT                   /note="Y -> C (in CIPA; dbSNP:rs121964869)"
FT                   /evidence="ECO:0000269|PubMed:11310631"
FT                   /id="VAR_068481"
FT   VARIANT         444
FT                   /note="R -> Q (in dbSNP:rs56320207)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041466"
FT   VARIANT         452
FT                   /note="R -> C (in dbSNP:rs34900547)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041467"
FT   VARIANT         476..796
FT                   /note="Missing (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079403"
FT   VARIANT         492
FT                   /note="E -> K (in CIPA; dbSNP:rs144901788)"
FT                   /evidence="ECO:0000269|PubMed:22302274"
FT                   /id="VAR_068482"
FT   VARIANT         517
FT                   /note="G -> E (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, small decrease in
FT                   the percentage of cells differentiated into neuronal
FT                   phenotype, but in differentiated cells, the average neurite
FT                   length is comparable to wild-type; no effect on
FT                   N-glycosylation, subcellular location, nor on basal and
FT                   NGF-induced autophosphorylation; loss of NGF-stimulated
FT                   calcium flux; dbSNP:rs606231467)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077472"
FT   VARIANT         522
FT                   /note="G -> E (in CIPA; no effect on N-glycosylation, nor
FT                   on subcellular location; reduced basal autophosphorylation
FT                   and complete loss of NGF-induced autophosphorylation; loss
FT                   of NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077473"
FT   VARIANT         522
FT                   /note="G -> R (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs1571699266)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009626"
FT   VARIANT         566
FT                   /note="M -> T (in dbSNP:rs55892037)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041468"
FT   VARIANT         572
FT                   /note="I -> S (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:18077166"
FT                   /id="VAR_077474"
FT   VARIANT         577
FT                   /note="G -> R (in CIPA; loss of function; processed as
FT                   wild-type but shows significantly diminished
FT                   autophosphorylation in both neuronal and non-neuronal
FT                   cells; dbSNP:rs121964866)"
FT                   /evidence="ECO:0000269|PubMed:10567924,
FT                   ECO:0000269|PubMed:10982191, ECO:0000269|PubMed:11159935,
FT                   ECO:0000269|PubMed:8696348"
FT                   /id="VAR_004103"
FT   VARIANT         587
FT                   /note="M -> V (in CIPA; dbSNP:rs121964870)"
FT                   /evidence="ECO:0000269|PubMed:10233776"
FT                   /id="VAR_009627"
FT   VARIANT         596
FT                   /note="D -> N (in CIPA; abolishes autophosphorylation)"
FT                   /evidence="ECO:0000269|PubMed:28177573"
FT                   /id="VAR_079404"
FT   VARIANT         604
FT                   /note="H -> Y (in dbSNP:rs6336)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009628"
FT   VARIANT         613
FT                   /note="G -> V (in dbSNP:rs6339)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:11159935,
FT                   ECO:0000269|PubMed:11310631, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009629"
FT   VARIANT         649
FT                   /note="R -> Q (in CIPA; dbSNP:rs786205449)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079405"
FT   VARIANT         649
FT                   /note="R -> W (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs369353892)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009630"
FT   VARIANT         654
FT                   /note="R -> C (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs764992664)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:22302274"
FT                   /id="VAR_009631"
FT   VARIANT         657
FT                   /note="L -> P (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, loss of
FT                   differentiation into neuronal phenotype; partially
FT                   decreased N-glycosylation; reduced expression at the plasma
FT                   membrane; reduced basal autophosphorylation and complete
FT                   loss of NGF-induced autophosphorylation; loss of
FT                   NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077475"
FT   VARIANT         674
FT                   /note="D -> Y (in CIPA; might impair the function of the
FT                   enzyme without compromising autophosphorylation;
FT                   dbSNP:rs80356677)"
FT                   /evidence="ECO:0000269|PubMed:10982191,
FT                   ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:28177573"
FT                   /id="VAR_009632"
FT   VARIANT         695
FT                   /note="P -> L (in CIPA; dbSNP:rs121964868)"
FT                   /evidence="ECO:0000269|PubMed:10861667"
FT                   /id="VAR_009633"
FT   VARIANT         699
FT                   /note="I -> T (in CIPA; partially decreased
FT                   N-glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal autophosphorylation and complete loss of
FT                   NGF-induced autophosphorylation; loss of NGF-stimulated
FT                   calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077476"
FT   VARIANT         700
FT                   /note="L -> P (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:28328124"
FT                   /id="VAR_079406"
FT   VARIANT         714
FT                   /note="G -> S (in CIPA; processed as wild-type but shows
FT                   significantly diminished autophosphorylation in both
FT                   neuronal and non-neuronal cells; dbSNP:rs770727871)"
FT                   /evidence="ECO:0000269|PubMed:10330344,
FT                   ECO:0000269|PubMed:11159935"
FT                   /id="VAR_009634"
FT   VARIANT         717
FT                   /note="L -> R (in CIPA)"
FT                   /evidence="ECO:0000269|PubMed:18077166"
FT                   /id="VAR_077477"
FT   VARIANT         752
FT                   /note="C -> S (in CIPA; unknown pathological significance;
FT                   following transfection in neuroblastoma cells and NGF
FT                   treatment, no effect on neurite outgrowth, nor neurite
FT                   length; no effect on N-glycosylation, subcellular location,
FT                   basal and NGF-induced autophosphorylation, nor on
FT                   NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077478"
FT   VARIANT         763
FT                   /note="C -> S (in CIPA; following transfection in
FT                   neuroblastoma cells and NGF treatment, decreased percentage
FT                   of cells differentiated into neuronal phenotype and reduced
FT                   neurite length compared with wild-type; slightly decreased
FT                   N-glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal and NGF-induced autophosphorylation; small
FT                   reduction in NGF-stimulated calcium flux)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077479"
FT   VARIANT         771
FT                   /note="R -> C (in CIPA; partially decreased
FT                   N-glycosylation; reduced expression at the plasma membrane;
FT                   reduced basal autophosphorylation and complete loss of
FT                   NGF-induced autophosphorylation; loss of NGF-stimulated
FT                   calcium flux; dbSNP:rs1324983370)"
FT                   /evidence="ECO:0000269|PubMed:27676246"
FT                   /id="VAR_077480"
FT   VARIANT         780
FT                   /note="R -> P (in CIPA; loss of function;
FT                   dbSNP:rs35669708)"
FT                   /evidence="ECO:0000269|PubMed:10090906"
FT                   /id="VAR_009635"
FT   VARIANT         780
FT                   /note="R -> Q (in dbSNP:rs35669708)"
FT                   /evidence="ECO:0000269|PubMed:10443680,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_009636"
FT   VARIANT         790
FT                   /note="V -> I (in dbSNP:rs55948542)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041469"
FT   MUTAGEN         496
FT                   /note="Y->F: Loss of interaction with SHC1 and altered
FT                   phosphorylation of SHC1. Altered neurite outgrowth and
FT                   altered activation of the MAPK pathway; when associated
FT                   with F-791."
FT                   /evidence="ECO:0000269|PubMed:8155326"
FT   MUTAGEN         540..541
FT                   /note="LV->AA: Abolishes interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         544
FT                   /note="K->A: No effect on interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         544
FT                   /note="K->N: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:1281417,
FT                   ECO:0000269|PubMed:8155326"
FT   MUTAGEN         610..611
FT                   /note="LL->AA: No effect on interaction with GGA3."
FT                   /evidence="ECO:0000269|PubMed:26446845"
FT   MUTAGEN         791
FT                   /note="Y->F: Loss of interaction with PLCG1 and altered
FT                   phosphorylation of PLCG1. Altered neurite outgrowth and
FT                   altered activation of the MAPK pathway; when associated
FT                   with F-496."
FT                   /evidence="ECO:0000269|PubMed:7510697,
FT                   ECO:0000269|PubMed:8155326"
FT   CONFLICT        263
FT                   /note="V -> L (in Ref. 1; AAA36770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        300
FT                   /note="C -> S (in Ref. 1; AAA36770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        529
FT                   /note="C -> S (in Ref. 10; CAA59936)"
FT                   /evidence="ECO:0000305"
FT   STRAND          38..40
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          43..46
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   TURN            57..61
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          69..72
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   HELIX           84..86
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          94..97
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   HELIX           110..112
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   TURN            133..135
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          142..144
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   HELIX           154..156
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   HELIX           157..164
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   HELIX           171..173
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          178..181
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          195..199
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          211..218
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          227..230
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          234..238
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          244..253
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   TURN            257..260
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          263..265
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          276..278
FT                   /evidence="ECO:0007829|PDB:2IFG"
FT   STRAND          284..290
FT                   /evidence="ECO:0007829|PDB:1WWW"
FT   STRAND          298..305
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   STRAND          312..317
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   STRAND          326..333
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   STRAND          342..350
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   HELIX           353..355
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   STRAND          357..365
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   STRAND          368..376
FT                   /evidence="ECO:0007829|PDB:1HE7"
FT   HELIX           418..441
FT                   /evidence="ECO:0007829|PDB:2N90"
FT   STRAND          476..478
FT                   /evidence="ECO:0007829|PDB:5KML"
FT   HELIX           490..492
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   TURN            494..496
FT                   /evidence="ECO:0007829|PDB:1SHC"
FT   HELIX           507..509
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          510..517
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          520..522
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          524..533
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   TURN            534..536
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   STRAND          537..545
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           552..566
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          575..579
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          581..584
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          586..590
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           597..603
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          605..607
FT                   /evidence="ECO:0007829|PDB:4F0I"
FT   HELIX           608..611
FT                   /evidence="ECO:0007829|PDB:4PMP"
FT   STRAND          615..617
FT                   /evidence="ECO:0007829|PDB:6NSS"
FT   STRAND          619..621
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   HELIX           624..643
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          646..648
FT                   /evidence="ECO:0007829|PDB:5KML"
FT   HELIX           653..655
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          656..659
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           660..662
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   STRAND          663..666
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           672..675
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   HELIX           677..679
FT                   /evidence="ECO:0007829|PDB:4PMP"
FT   STRAND          680..683
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   TURN            684..686
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   STRAND          687..689
FT                   /evidence="ECO:0007829|PDB:5KMI"
FT   HELIX           691..693
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           696..701
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           706..721
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   TURN            722..724
FT                   /evidence="ECO:0007829|PDB:5JFV"
FT   TURN            727..730
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           733..742
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           754..763
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           768..770
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           774..786
FT                   /evidence="ECO:0007829|PDB:5JFW"
FT   HELIX           789..793
FT                   /evidence="ECO:0007829|PDB:5KMI"
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
